EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Acquired by Cubist Systematic Strategies LLC

Cubist Systematic Strategies LLC lifted its holdings in shares of EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT - Free Report) by 211.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 99,498 shares of the company's stock after acquiring an additional 67,527 shares during the quarter. Cubist Systematic Strategies LLC owned 0.15% of EyePoint Pharmaceuticals worth $741,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of EYPT. RA Capital Management L.P. purchased a new stake in EyePoint Pharmaceuticals during the 4th quarter worth approximately $23,705,000. TCG Crossover Management LLC grew its position in shares of EyePoint Pharmaceuticals by 287.3% during the fourth quarter. TCG Crossover Management LLC now owns 3,572,335 shares of the company's stock worth $26,614,000 after buying an additional 2,650,000 shares in the last quarter. Adage Capital Partners GP L.L.C. increased its stake in shares of EyePoint Pharmaceuticals by 51.7% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,750,000 shares of the company's stock worth $42,838,000 after buying an additional 1,958,580 shares during the last quarter. Federated Hermes Inc. raised its holdings in EyePoint Pharmaceuticals by 92.7% in the fourth quarter. Federated Hermes Inc. now owns 3,707,445 shares of the company's stock valued at $27,620,000 after acquiring an additional 1,783,765 shares in the last quarter. Finally, Vanguard Group Inc. boosted its stake in EyePoint Pharmaceuticals by 24.8% during the 4th quarter. Vanguard Group Inc. now owns 3,803,227 shares of the company's stock valued at $28,334,000 after acquiring an additional 755,045 shares during the last quarter. Institutional investors and hedge funds own 99.41% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on EYPT. StockNews.com raised shares of EyePoint Pharmaceuticals to a "sell" rating in a research report on Friday, March 14th. Chardan Capital lowered their price objective on EyePoint Pharmaceuticals from $33.00 to $27.00 and set a "buy" rating for the company in a report on Thursday, May 8th. HC Wainwright restated a "buy" rating and set a $22.00 price objective on shares of EyePoint Pharmaceuticals in a research note on Thursday, March 6th. Finally, Mizuho decreased their target price on EyePoint Pharmaceuticals from $30.00 to $26.00 and set an "outperform" rating for the company in a research report on Friday. One investment analyst has rated the stock with a sell rating and nine have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus price target of $25.38.

EyePoint Pharmaceuticals Stock Up 7.2%

EYPT stock traded up $0.41 during midday trading on Friday, reaching $6.13. The company had a trading volume of 1,117,415 shares, compared to its average volume of 817,212. The stock has a 50 day moving average price of $5.91 and a 200 day moving average price of $7.33. EyePoint Pharmaceuticals, Inc. has a fifty-two week low of $3.91 and a fifty-two week high of $13.99. The firm has a market capitalization of $421.81 million, a PE ratio of -3.07 and a beta of 1.58.

EyePoint Pharmaceuticals (NASDAQ:EYPT - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.65). EyePoint Pharmaceuticals had a negative net margin of 226.57% and a negative return on equity of 43.01%. The firm had revenue of $24.50 million during the quarter, compared to analyst estimates of $8.84 million. Research analysts predict that EyePoint Pharmaceuticals, Inc. will post -2.13 EPS for the current year.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.